New report backs SciBase’s melanoma detection AI device
Source: Medical Device Network, September 2024
Swedish medical detection company SciBase Holding has seen its artificial intelligence (AI) powered device for detecting melanomas, dubbed Nevisense, validated as part of a consensus report that found it effective in detecting potential cancers.
Published in the Journal of Drugs in Dermatology (JDD), the study saw ten dermatologists reviewing 200 published articles on the topics of non-invasive diagnostic and prognostic testing for cutaneous melanoma (CM) including gene expression profiling (GEP) and electrical impedance spectroscopy (EIS) with the researchers agreeing to a consensus that the combination of methods is able to significantly increase detection.
The research concluded that 2-GEP tests and EIS can aid in the precise diagnosis of clinically indeterminate lesions. According to SciBase, Nevisense is the only US Food and Drug Administration (FDA) approved device for the early detection of skin cancers utilising both systems of treatment.